{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:28:10Z","timestamp":1793377690212,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,3]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n \n This study aimed to assess the diagnostic performance of [\n 18<\/jats:sup>\n F]FAPI-42 PET\/CT and compare it with that of 2-[\n 18<\/jats:sup>\n F]FDG PET\/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [\n 18<\/jats:sup>\n F]FAPI-42 PET\/CT as part of this study; of which, 11 additionally underwent 2-[\n 18<\/jats:sup>\n F]FDG PET\/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [\n 18<\/jats:sup>\n F]FAPI-42 PET\/CT and biomarkers affecting the uptake of [\n 18<\/jats:sup>\n F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [\n 18<\/jats:sup>\n F]FAPI-42 and 2-[\n 18<\/jats:sup>\n F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 161 lesions were detected in 27 (64%) patients on [\n 18<\/jats:sup>\n F]FAPI-42 PET\/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUV\n max<\/jats:sub>\n , 4.7 versus 3.7 versus 3.0 versus 2.2, respectively;\n P<\/jats:italic>\n < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUV\n max<\/jats:sub>\n : 2.4 versus 3.2,\n P<\/jats:italic>\n = 0.56; 2.9 versus 2.4,\n P<\/jats:italic>\n = 0.0935; 2.8 versus 2.6,\n P<\/jats:italic>\n = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[\n 18<\/jats:sup>\n F]FDG than that of [\n 18<\/jats:sup>\n F]FAPI-42 (SUV\n max<\/jats:sub>\n , 2.6 versus 2.1;\n P<\/jats:italic>\n = 0.026). However, the SUV\n max<\/jats:sub>\n of [\n 18<\/jats:sup>\n F]FAPI-42 was higher than that of 2-[\n 18<\/jats:sup>\n F]FDG in local recurrences and lymphatic lesions (SUV\n max<\/jats:sub>\n , 4.2 versus 2.9 and 3.9 versus 3.4, respectively;\n P<\/jats:italic>\n > 0.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n [\n 18<\/jats:sup>\n F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [\n 18<\/jats:sup>\n F]FAPI-42 PET\/CT is comparable with that of 2-[\n 18<\/jats:sup>\n F]FDG PET\/CT in such patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00259-022-06067-2","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T01:08:12Z","timestamp":1670634492000},"page":"1205-1215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["[18F]FAPI-42 PET\/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET\/CT"],"prefix":"10.1007","volume":"50","author":[{"given":"Xingyu","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"6067_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin."},{"key":"6067_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/JCO.2017.74.5497","volume":"36","author":"X Shen","year":"2018","unstructured":"Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, et al. Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer. J Clin Oncol. 2018;36:438\u201345. https:\/\/doi.org\/10.1200\/JCO.2017.74.5497.","journal-title":"J Clin Oncol."},{"key":"6067_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamasurg.2018.2659","volume":"153","author":"ML Hung","year":"2018","unstructured":"Hung ML, Wu JX, Li N, Livhits MJ, Yeh MW. Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer. JAMA Surg. 2018;153:1098\u2013104. https:\/\/doi.org\/10.1001\/jamasurg.2018.2659.","journal-title":"JAMA Surg."},{"key":"6067_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid."},{"key":"6067_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454\u201363. https:\/\/doi.org\/10.1002\/prca.201300095.","journal-title":"Proteomics Clin Appl."},{"key":"6067_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med Off Publ Soc Nucl Med. 2019;60:801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"6067_CR7","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.1007\/s13277-015-4684-4","volume":"37","author":"WY Sun","year":"2016","unstructured":"Sun WY, Jung WH, Koo JS. Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma. Tumour Biol. 2016;37:8197\u2013207. https:\/\/doi.org\/10.1007\/s13277-015-4684-4.","journal-title":"Tumour Biol."},{"key":"6067_CR8","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/OTT.S294725","volume":"14","author":"S Wen","year":"2021","unstructured":"Wen S, Qu N, Ma B, Wang X, Luo Y, Xu W, et al. Cancer-associated fibroblasts positively correlate with dedifferentiation and aggressiveness of thyroid cancer. Onco Targets Ther. 2021;14:1205\u201317. https:\/\/doi.org\/10.2147\/OTT.S294725.","journal-title":"Onco Targets Ther."},{"key":"6067_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/thy.2021.0412","volume":"32","author":"S Ballal","year":"2022","unstructured":"Ballal S, Yadav MP, Moon ES, Roesch F, Kumari S, Agarwal S, et al. Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study. Thyroid. 2022;32:65\u201377. https:\/\/doi.org\/10.1089\/thy.2021.0412.","journal-title":"Thyroid."},{"key":"6067_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68 Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386\u201392.","journal-title":"J Nucl Med."},{"key":"6067_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiol.212430","volume":"304","author":"H Fu","year":"2022","unstructured":"Fu H, Wu J, Huang J, Sun L, Wu H, Guo W, et al. (68)Ga fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with (18)F-FDG PET\/CT. Radiology. 2022;304:397\u2013405. https:\/\/doi.org\/10.1148\/radiol.212430.","journal-title":"Radiology."},{"key":"6067_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/RLU.0000000000004038","volume":"47","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zheng S, Zhang J, Yao S, Miao W. Pleural metastasis of papillary thyroid cancer depicted by 68Ga-FAPI PET\/CT. Clin Nucl Med. 2022;47:467\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000004038.","journal-title":"Clin Nucl Med."},{"key":"6067_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12020-021-02668-3","volume":"73","author":"J Wu","year":"2021","unstructured":"Wu J, Ou L, Zhang C. Comparison of (68)Ga-FAPI and (18)F-FDG PET\/CT in metastases of papillary thyroid carcinoma. Endocrine. 2021;73:767\u20138. https:\/\/doi.org\/10.1007\/s12020-021-02668-3.","journal-title":"Endocrine."},{"key":"6067_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/RLU.0000000000003569","volume":"46","author":"H Fu","year":"2021","unstructured":"Fu H, Fu J, Huang J, Su X, Chen H. 68Ga-FAPI PET\/CT in thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy. Clin Nucl Med. 2021;46:427\u201330. https:\/\/doi.org\/10.1097\/RLU.0000000000003569.","journal-title":"Clin Nucl Med."},{"key":"6067_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s12149-022-01742-8","volume":"36","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zheng S, Zhang J, Yao S, Miao W. (68)Ga-DOTA-FAPI-04 PET\/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med. 2022;36:610\u201322. https:\/\/doi.org\/10.1007\/s12149-022-01742-8.","journal-title":"Ann Nucl Med."},{"key":"6067_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575\u201384. https:\/\/doi.org\/10.1007\/s11307-015-0866-0.","journal-title":"Mol Imaging Biol."},{"key":"6067_CR17","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [(18)F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET\/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-022-05758-0.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6067_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2967\/jnumed.118.221671","volume":"60","author":"T Liu","year":"2019","unstructured":"Liu T, Liu C, Xu X, Liu F, Guo X, Li N, et al. Preclinical evaluation and pilot clinical study of Al(18)F-PSMA-BCH for prostate cancer PET imaging. J Nucl Med Off Publ Soc Nucl Med. 2019;60:1284\u201392. https:\/\/doi.org\/10.2967\/jnumed.118.221671.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"6067_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","volume":"12","author":"K Hu","year":"2022","unstructured":"Hu K, Li J, Wang L, Huang Y, Li L, Ye S, et al. Preclinical evaluation and pilot clinical study of [(18)F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta Pharm Sin B. 2022;12:867\u201375. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.032.","journal-title":"Acta Pharm Sin B."},{"key":"6067_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6067_CR21","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1007\/s00259-021-05470-5","volume":"48","author":"S Wang","year":"2021","unstructured":"Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48:4259\u201371. https:\/\/doi.org\/10.1007\/s00259-021-05470-5.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6067_CR22","doi-asserted-by":"publisher","unstructured":"Maisto C, Aurilio M, Morisco A, de Marino R, Buonanno Recchimuzzo MJ, Carideo L, et al. Analysis of pros and cons in using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007: production, costs, and PET\/CT applications in patients with prostate cancer. Molecules (Basel, Switzerland). 2022:27. https:\/\/doi.org\/10.3390\/molecules27123862.","DOI":"10.3390\/molecules27123862"},{"key":"6067_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/EJE-19-0261","volume":"181","author":"W Qichang","year":"2019","unstructured":"Qichang W, Lin B, Gege Z, Youjia Z, Qingjie M, Renjie W, et al. Diagnostic performance of 18F-FDG-PET\/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol. 2019;181:93\u2013102. https:\/\/doi.org\/10.1530\/EJE-19-0261.","journal-title":"Eur J Endocrinol."},{"key":"6067_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/2326-6066.CIR-16-0011","volume":"4","author":"E Pure","year":"2016","unstructured":"Pure E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res. 2016;4:269\u201378. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0011.","journal-title":"Cancer Immunol Res."},{"key":"6067_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1089\/thy.2015.0482","volume":"26","author":"SA Gulec","year":"2016","unstructured":"Gulec SA, Kuker RA, Goryawala M, Fernandez C, Perez R, Khan-Ghany A, et al. (124)I PET\/CT in patients with differentiated thyroid cancer: clinical and quantitative image analysis. Thyroid. 2016;26:441\u20138. https:\/\/doi.org\/10.1089\/thy.2015.0482.","journal-title":"Thyroid."},{"key":"6067_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00259-007-0601-4","volume":"35","author":"LS Freudenberg","year":"2008","unstructured":"Freudenberg LS, Jentzen W, Muller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging. 2008;35:502\u20138. https:\/\/doi.org\/10.1007\/s00259-007-0601-4.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6067_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/RLU.0000000000003505","volume":"46","author":"D Wu","year":"2021","unstructured":"Wu D, Plyku D, Kulkarni K, Garcia C, Atkins F, Tefera E, et al. Optimal time for 124I PET\/CT imaging in metastatic differentiated thyroid cancer. Clin Nucl Med. 2021;46:283\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003505.","journal-title":"Clin Nucl Med."},{"key":"6067_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/jclinpath-2020-207357","volume":"74","author":"J Ham","year":"2021","unstructured":"Ham J, Wang B, Po JW, Singh A, Niles N, Lee CS. Cancer-associated fibroblasts (CAFs) in thyroid papillary carcinoma: molecular networks and interactions. J Clin Pathol. 2021;74:759\u201365. https:\/\/doi.org\/10.1136\/jclinpath-2020-207357.","journal-title":"J Clin Pathol."},{"key":"6067_CR29","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1158\/0008-5472.CAN-15-2351","volume":"76","author":"LA Jolly","year":"2016","unstructured":"Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, et al. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 2016;76:1804\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2351.","journal-title":"Cancer Res."},{"key":"6067_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.7150\/thno.22717","volume":"8","author":"C Shangguan","year":"2018","unstructured":"Shangguan C, Gan G, Zhang J, Wu J, Miao Y, Zhang M, et al. Cancer-associated fibroblasts enhance tumor (18)F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT. Theranostics. 2018;8:1376\u201388. https:\/\/doi.org\/10.7150\/thno.22717.","journal-title":"Theranostics."},{"key":"6067_CR31","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.21873\/anticanres.11129","volume":"36","author":"T Fujii","year":"2016","unstructured":"Fujii T, Yajima R, Kurozumi S, Higuchi T, Obayashi S, Tokiniwa H, et al. Clinical significance of 18F-FDG-PET in Invasive lobular carcinoma. Anticancer Res. 2016;36:5481\u20135. https:\/\/doi.org\/10.21873\/anticanres.11129.","journal-title":"Anticancer Res."},{"key":"6067_CR32","doi-asserted-by":"publisher","first-page":"797960","DOI":"10.3389\/fonc.2021.797960","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Ma L, Hou H, Gao F, Tao W. FAPI PET\/CT in the diagnosis of abdominal and pelvic tumors. Front Oncol. 2021;11:797960. https:\/\/doi.org\/10.3389\/fonc.2021.797960.","journal-title":"Front Oncol."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06067-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T22:12:28Z","timestamp":1676499148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06067-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6067"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06067-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"9 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Affiliated Hospital of Guilin Medical University (no. 2022WJWZCLL-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants or their parents included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}